Logo Prima Biomed

Welcome to the Newsroom

08 September 2017

Prima Secures Japanese Patent Grant for IMP731 Antibody



SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”, the “Company”) announces the grant of Japanese patent no. 6177735 entitled “Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease” by the Japanese Patent Office.